Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines

Drug Profile

Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines

Alternative Names: 268664; EBV gp350 - Henogen; EBV vaccine 268664 - GlaxoSmithKline; GSK Biologicals' EBV vaccine (268664); GSK-268664; HENO 4; Recombinant gp350 vaccine for infectious mononucleosis - GlaxoSmithKline

Latest Information Update: 18 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune Vaccines
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epstein-Barr virus infections; Infectious mononucleosis; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 20 Apr 2011 Epstein-Barr virus vaccine is still in phase II development
  • 06 Jul 2009 Henogen has been acquired by Novasep
  • 27 May 2009 EBV vaccine is still in phase II development trials for Epstein-Barr virus infections in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top